HOLD CRM

0 shares at $186.02 on 2026-05-04

Reasoning

HOLD pending catalyst clarification. CRM playbook thesis (Action 246) recommends $300 invest to add modestly ahead of May 27 earnings. However, current position is ~3.9% of portfolio and near cost basis (~7.4% unrealized gain). While SaaS recovery narrative is sound and $25B buyback provides support, Rule 27 (macro fragility window with geopolitical escalation) caps new deployment at $500/day total. With ANET trim and GOOGL trim generating proceeds, deploying into CRM now would bring total new buys today to $600 (AMZN $300 + CRM $300), exactly at the Rule 27 limit. Additionally, CRM has May 27 earnings (binary event); Rule 29 stipulates keeping total CRM exposure under 5%. Current position + $300 spend (~1.7 shares at $186.31) would result in ~4.8% exposure, safely under 5%, but the micro-deployment does not materially advance the position for the earnings catalyst. Defer CRM addition by 1-2 days to allow geopolitical situation to stabilize, then reassess with clearer signal conviction.

Thesis

Salesforce is down ~30% YTD but near cost basis for this position. The value thesis rests on: (1) a $25B share buyback program providing downside support, (2) Agentforce AI platform as a potential re-rating catalyst with earnings due May 27, (3) analyst consensus Buy with avg PT of ~$279 implying ~50% upside from current levels, and (4) enterprise software broadly recovering with Atlassian's 28% earnings beat demonstrating enterprise AI spend is real. Key risks include decelerating organic growth (CRM market share fell from 21.7% to 20.7%), activist pressure (Starboard Value proxy fight at May 28 annual meeting), and high-single-digit organic growth being priced as a premium software name. The May 27 earnings report is the key catalyst. (long, medium confidence)